Dipyridamole 부하 심근 SPECT에서 Dipyridamole의 작용과 부작용

고창순(Chang Soon Koh),이명철(Myung Chul Lee),정준기(June Key Chung),이동수(Dong Soo Lee),최창운(Chang Woon Choi),배상균(Sang Kyun Bae),양형인(Hyung In Yang),여정석(Jeong Suk Yeo) 대한핵의학회 1993 핵의학 분자영상 Vol.27 No.2

N/A Dipyridamole is an agent that may be used to noninvasively evaluate coronary artery disease. The effect of dipyridamole infusion its generally related to its induced peripheral vasodilatory effect. In normal person, heart rate is generally increased slightly while blood pressure decrease, but the achieved double product and related myocardial oxygen consumption have no significant change. The purpose of this study is to examine the effect and side effect of dipyridamole, and to compare different response to dipyridamole among the patients. We evaluated 847 patients who underwent dipyridamole stress myocardial SPECT. 93.6% of them had induced hypotension 0.9% showed no change of blood pressure, 5.5% had increased blood pressure 8.3% had no change of pulse rate more than 10% of basal pulse rate. Among diabetes, 16.9% was not change of pulse rate, 6.7% in non-diabetes. There was no significant correlation between age and rate pressure product rest(RPPr), in patients without perfusion defects on SPECT(y=7.1x+48.4r=0.13 p>0.01). As increasing age, RPPs/RPPr was declined(y=-11.6x+68.9 r=0.17 p〈0.01), similar results were obtained in patients with perfusion defect. The size of perfusion defect on myocardial SPECT have no correlation between RPPr and RPPs/RPPr. The side effects of dipyridamole included chest pain and chest tightness, headache, abdominal pain, dizzness, nausea, and dyspnea. As increasing age, dipyridamole-induced cardiac work at rest was increased, cardiac response to dipyridamole was decreased.

종양 이식 백서에서 3-<131I>iodo-O-methyl-L-alpha-methyltyrosine 의 체내 동태 연구 - L-3-<131I>iodo-alpha-methyltyrosine 와 비교

최창운,양승대,우광선,정위섭,임수정,서용섭,전권수,안순혁,이종두,홍성운,임상무 ( Chang Woon Choi,Seung Dae Yang,Kwang Sun Woo,Wee Sup Chung,Soo Jung Lim,Yong Sup Suh,Kwon Soo Chun,Soon Hyuk Ahn,Jong Doo Lee,Sung Soon Hong,Sang Moo Lim 대한핵의학회 1998 핵의학 분자영상 Vol.32 No.3

Purpose : The aim of this sutdy was to evaluate the feasibility of 3-[131I]Iodo-O-methyl-L-a-methyltyrosine ([131I]OMINT) as an agent for tumor image. Materlals and Methods: After synthesis of 4-O-methyl-L-a-methyltyrosine (OMAMT), OMAMT was labeled with 131I using Iodogen method. In viro cellular uptake study was performed using 9 L gliosarcoma cells at various time points upto 4 hr. The biodistribution (five rats implanted with the 9 L gliosarcoma cells per group) was evaluated at 30 min, 2 hr, 24 hr after iv injection of 3.7 MBq [131I]OMIMT or L-3-[131I]iodo-a-methyltyrosine ([131I]IMT). Gamma camera images were obtained at 30min, 2 hr, and 24 hr. Results : [131I]OMINT uptake was 3.3 times and 2.5 times higher than [131I]IMT uptake at 30 min and 60 min, respectively and same after 2 hr in in vitro sutdy using 9L gliosarcoma cells. Maximum accumulation in tumor occurred at 30 min for both [131IOMINT and [131I]IMT in tumor bearing rats. The tumor uptake of [131I]OMINT was significantly higher than that of [131I]IMT in tumor bearing rats. The tumor uptake of [131I]OMIMT was significantly higher than that of [131I]IMT at early time point studied (3.74 +- 0.48 vs 0.38 +- 0.17% ID/g at 30 min and 2.40 +- 0.17 vs 0.24 +- 0.03% ID/g at 2 hr, respectively, p<0.01). However, the tumor uptake of both radiolabels were not significantly different at 24 hr (0.04 +- 0.01 vs 0.05 +- 0.01% ID/g). Tumor was visualized as early as at 30 min in gamma camera images. Conclusion : These data suggested that [131I]OMIMT might be a useful tumor imaging agent and has more advantage for the tumor imaging compared to [131I]IMT. (korean J NuclMed 1998;32;290-7)

위암환자에서 99mTc - MDP 스캔에 의한 골전이 평가

최창운,김상은,이동수,여정석,안규리,정준기,이명철,김노경,고창순 ( Chang Woon Choi,Sang Eun Kim,Dong Soo Lee,Jung Seok Lyeo,Cu Rie Ahn,Jung Key Chung,Myung Chul Lee,Noe Kyung Kim,Chang Soon Koh ) 대한핵의학회 1991 핵의학 분자영상 Vol.25 No.2

악성종양에서 골수면역신티그라피를 이용한 골수전이의 평가 : $^{99m}Tc$-MDP 뼈스캔과의 비교

이경한,최창운,방영주,정준기,정홍근,이명철,김병국,김노경,고창순,Lee, Kyung-Han,Choi, Chang-Woon,Bang, Yung-Jue,Chung, Jun-Key,Chung, Hong-Keun,Lee, Myoung-Chul,Kim, Byoung-Kook,Kim, Noe-Kyeong,Koh, Chang-Soon 대한핵의학회 1994 핵의학 분자영상 Vol.28 No.1

Although bone scan is a highly sensitive test for detecting bone metastasis, its findings are often limited in specificity and cannot be used for assessing the bone marrow. Bone marrow scintigraphy may provide useful information but previous experience with radiolabelled colloid has been disappointing. Recently, $^{99m}Tc$ labeled anti-granulocyte monoclonal antibody (anti-NCA-95 MAb) has been introduced as a new bone marrow imaging agent. To evaluate the usefulness of $^{99m}Tc$ anti-NCA MAb bone marrow scans for detecting skeletal metastasis, bone marrow scans of 44 malignant tumor patients were evaluated and compared with bone scan findings. Bone scan showed abnormal lesions in 26(59%) cases, and 18 of these patients also had an abnormal bone marrow scan. Seven of the 8 patients who had normal bone marrow scan despite bone scan lesions were confirmed to be free from metastasis. There was one case with a marrow defect despite normal bone scan but the presence of metastasis was not determined due to loss of follow up. Bone scan demonstrated a total of 64 lesions while bone marrow scan showed 38 lesions. Fifty percent (32/64) of the bone scan lesions had matching marrow defects while the remaining 50% did not. Most of these non matched lesions were suggested to be nonspecific lesions such as rib fractures or degenerative change. Meanwhile bone marrow scan was able to detect 6 new lesions not detected by bone scan, bit metastasis in each lesion was not confirmed. Bone marrow scan was also helpful in assessing equivocal bone scan lesions to be of metastatic nature in 10 patients by demonstrating a matched marrow defect. Thus $^{99m}Tc$ anti-NCA MAb bone marrow scan can help exclude metastasis in patients with nonspecific bone scan lesions and may be able to detect metastatic lesions not seen with bone scan. It appears useful as a complementary study to bone scan in evaluating malignant tumor patients.

악성종양에서 골수면역신티그라피를 이용한 골수전이의 평가 : 99mTc-MDP 뼈스캔과의 비교

고창순(Chang Soon Koh),김노경(Noe Kyeong Kim),김병국(Byoung Kook Kim),최창운(Chang Woon Choi),정준기(Jun Key Chung),방영주(Yung Jue Bang),이경한(Kyung Han Lee),정홍근(Hong Keun Chung),이명철(Myoung Chul Lee) 대한핵의학회 1994 핵의학 분자영상 Vol.28 No.1

N/A Although bone scan is a highly sensitive test for detecting bone metastasis, its findings are often limited in specificity and cannot be used for assessing the bone marrow. Bone marrow scintigraphy may provide useful information but previous experience with radiolabelled colloid has been disappointing. Recently, 99mTc labeled anti-granulocyte rnonoclonal antibody (anti-NCA-95 MAb) has been introdueed as a new bone marrow imaging agent. To evaluate the usefulness of 99mTc anti-NCA MAb bone marrow scans for detecting skeietal metastasis, bone marrow scans of 44 malignant tumor patients were evaluated and compared with bone scan fmdings. Bone scan showed abnormal lesions in 26(59%) cases, and 18 of these patients also had an abnormal bone marrow scan. Seven of the 8 patients who had normal bone marrow scan despite bone scan lesions were confirmed to be free from metastasis. There was one case with a marrow defect despite normal bone scan but the presence of metastasis was not determined due to loss of follow up. Bone scan demonstrated a total of 64 lesions while bone marrow scan showed 38 lesions. Fifty percent (32/64) of the bone scan lesions had matching marrow defects while the rernaining 50% did not. Most of these non matched lesions were suggested to be nonspecific 1esions such as rib fractures or degenerative change. Meanwhile bone marrow scan was able to detect 6 new lesions not detected by bone scan, but metastasis in each lesion was not confirmed. Bone marrow scan was also helpful in assessing equivocal bone scan lesions to be of metastatic nature in 10 patients by demonstrating a matched marrow defect. Thus 99mTc anti-NCA MAb bone marrow scan can help exclude metastasis in patients with nonspecific bone scan lesions and may be able to detect metastatic lesions not seen with bone scan. It appears useful as a complementary study to bone scan in evaluating malignant tumor patients.

전이성 분화 갑상선암에서 200mCi 방사성 옥소 치료효과 평가를 위한 혈청 Thyroglobulin 추적검사와 전신스캔의 의의

최창운(Chang Woon Choi),임상무(Sang Moo Lim),홍성운(Sung Woon Hong),윤종길(Jong Kil Yoon),이창희(Chang Hee Lee),정상훈(Sang Hoon Jeong),권교선(Gyo Seon Kwun) 대한핵의학회 1995 핵의학 분자영상 Vol.29 No.4

N/A Thirty-eight patients with metastatic well-differentiated thyroid carcinoma treated with 200mCi 131I were false negative serum thyroglobulin values during TSH suppression or at anti-thyroglobulin antibody(+) and discrepancies between findings of whole body scan and serum thyroglobulin level. After one to five cycles of 200mCi 131I therapy, complete remission and partial were achieved at 5.3% and 57.9%, respectively. We concluded that all of serum thyroglobulin, TSH, anti-thyroglobulin antibody, 131I or 123I whole body scan were necessary in follow up of metastatic well-differentiated thyroid carcinoma. Also, if there was no response after repetitive 200mCi 131I therapy, higher doses of 131I therapy should be considered.

악성 갈색세포종 및 갑상선수질암의 131I - MIBG 을 이용한 치료

최창운(Chang Woon Choi),임상무(Sang Moo Lim),홍성운(Sung Woon Hong),윤종길(Jong Kil Yoon),류백렬(Baek Yeol Ryoo),이창희(Chang Hee Lee),정상훈(Sang Hoon Jeong),천영국(Young Kug Cheon) 대한핵의학회 1995 핵의학 분자영상 Vol.29 No.3

N/A 131I-metaiodobenzylguanidine(MIBG) has been used for the diagnosis and treatment of neural crest tumors. We report our experience with this agent in 8 patients[l multiple endocrine neoplasia(MEN) type IIb; 2 malignant pheochromocytoma; 5 medullary thyroid carcinoma(MTC)]. The therapeutic procedure consisted of 30-200 mCi of 131I-MIBG administered by slow I.V. infusion, given at 3-6 months intervals. Cummulative activity ranged from 150 mCi to 410 mCi, in 1 to 4 courses. 131I-MIBG therapy resulted in significant disease free interval in 1 malignant pheochromocytoma(no measurable lesion)after sugery; complete hormonal and tumoral response in 2 MTC(1 MEN IIb); stable disease in 1 recurred pheochromocytoma(MEN IIb); stable disease but symptomatic improvement in 1 MTC; progressive disease in 1 malignant pheochromocytoma and 2 MTC. The patients who showed progression appeared to have large inoperable tumors or postoperative remnant tumors.

신경 베체트병 1례 신경학적 증상과 뇌 PET , SPECT , MRI 소견의 비교

최창운(Chang Woon Choi),김소연(So Yon Kim),조민구(Min Koo Cho),임상무(Sang Moo Lim),이권전(Gwon Jun Lee),김영중(Young Jung Kim),홍성운(Sung Woon Hong),김진욱(Jin Wook Kim),안민(Min An) 대한핵의학회 1998 핵의학 분자영상 Vol.32 No.6

We describe a 27-year-old man who developed gait disturbance and dysarthria 2 years after the onset of cardinal symptoms of Behcet's disease. Positron emission tomography with 18F-fluorodeoxyglucose revealed severe hypometabolism in the cerebellum, in accordance wih cerebellar symptoms and sign of the patient. However, single-photon emission tomography with Tc-99m-HMPAO and Tc-99m-ECD did not disclose significant perfusion abnormalities in the brain. Routine brain magnetic resonance imaging did not show signal abnormalities. The findings of imaging studies compared with neurological manifestations of the patient are discussed.

지방육종형성 동물모델에서 123I-15-(p-iodophenyl)-3-R , S-methylpentadecanoic acid ( BMIPP ) 의 생체분포와 생체영상

최창운(Chang Woon Choi),임상무(Sang Moo Lim),이태섭(Tae Sup Lee),서용섭(Yong Sup Suh),우광선,정위섭(Wee Sup Chung),임수정(Soo Jung Lim),오옥두(Ok Doo Awh) 대한핵의학회 2001 핵의학 분자영상 Vol.35 No.5

N/A Purpose: 123I-labeled fatty acids have been used in the evaluation of regional myocardial energy metabolism. This study aimed to evaluate the usefulness of 123I-BMIPP as a liposarcorna-imaging agent. Materials and Methods: We compared in vitro uptakes between liposarcoma(SW872) and glioma(9L) cell lines, and examined biodistribution and in vivo images of 123I-BMIPP in liposarcoma-bearing nude mice. Cold-BMIPP was labeled with 123I using Cu2+ as catalyst. After purification by Sep-pak, radiochemical purity was determined by TLC. We compared cellular uptake between glioma and liposarcoma after incubation of 5, 10, 15, 30, 60, 120, and 180 mins with culture medium containing I-BMIPP. The difference in biodistribution was determined between non-feeding (water only) group for 18 hr and feeding group in normal mice (n=6/group) at 0.5, 2, and 24 hr. In liposarcoma-bearing nude mice model, liposarcoma, SW872, cell lines were injected subcutaneously into the left thigh of nude mice. The biodistribution of 123I-BMIPP was evaluated at 0.5, 2, and 24 hr (n=5 / group) and in vivo image of 123I-BMIPP was obtained with gamma camera at 2 and 24 hr in liposarcorna-bearing nude mice. Results: Radiolabeling yield and radiochemical purity were 95% and above 99%, respectively. SW872 cell line showed more increased uptake than 9L with 1.5 times at 180 mins. The clearance of 'I-BMIPP in various tissues was more delayed in the non-feeding group than in the feeding group, especially at delayed time (24 hr) in normal mice, and the major excreting organ was the gastrointestinal tract. In liposarcoma-bearing nude mice, tumor/blood ratio of 123I-BMIPP was 0.94, 0.75, and 1.38 and tumor/muscle ratio was 0.66, 1.53, and 1.11 at 0.5, 2, and 24hr, respectively. 123I-BMIPP was selectively localized in liposarcoma at 24 hr image. Conclusions: These results suggest that 123I-BMIPP can be used as a liposarcoma-imaging agent. (Korean J Nucl Med 200135:324-333)

Taxol 방사면역측정을 위한 125I-Iodotyraminehemisuccinyltaxol ( 125ITHT ) 의 제조

최창운(Chang Woon Choi),임상무(Sang Moo Lim),오옥두(Ok Doo Awh),이태섭(Tae Sup Lee),최태현(Tae Hyun Choi),김현석(Hyun Suk Kim),홍준표(Jun Pyo Hong),이은숙(Eun Sook Lee) 대한핵의학회 2002 핵의학 분자영상 Vol.36 No.2

목적: Taxol(Paclitaxel)은 난소암과 유방암의 치료제로 사용되고 있으며, 치료시 적절한 체내 혈중농도를 유지함으로서 치료효과를 극대화하기 위해서는 taxol의 혈중농도를 측정할 수 있는 방사면역측정시스템에 표지항원으로 사용할 수 있는 taxol 유도체의 방사성표지화합물을 합성하고, 이를 이용하여 방사면역측정법을 시행할수 있는지의 여부를 확인하고자 하였다. 대상 및 방법: Taxol과 succinic anhydride를 무수 pyridine을 용매로 하여 반응시켜 hemisuccinyltaxol을 합성하고, 합성된 hemisuccinyltaxol과 tyramine을 isobutyl-chloroformate를 coupling agent로 사용하여 tyraminehemisuccinyltaxol을 합성하고 HPLC로 분리정제 하였다. 산화제인 Chloramine-T(5.25 ㎎/ml, 10㎕)를 사용하여 tyraminehemisuccinyltaxol(4 ㎎/ml, 30㎕)에 ^125l(l mCi)를 방사성요오드화하고 HPLC를 이용하여 표지수율을 산정하였다. 정제된 tyraminehenisuccinyltaxol과 ^125l-iodotyraminehemisuccinyltaxol을 80% acetonitrile 수용액에 녹여 4℃와 37℃로 보관하면서, 각 시간대별로 화학적 순도와 방사화학적 순도를 결정하여 그 안정도를 HPLC를 이용하여 확인하였다. [^125l]Iodotyraminehemisuccinyltaxol를 방사성표지항원으로 사용하여 taxol에 대한 단클론항체(3G5A7)의 역가를 검정하였으며, 0∼100nM 농도범위에서 taxol 농도의 증가에 따른 표준투여응답곡선을 작성하였다. 결과: Hemisuccinyltaxol은 79.9%의 수율로 합성되었으며, tyraminehemisuccinyltaxol의 합성수율은 19.5%였다. ^125l-iodotyraminehemisuccinyltaxol의 표지수율은 93%이었다. tyraminehemisuccinyltaxol은 7일까지도 96.5% 이상의 순도를 보여 비교적 안정함을 확인하였으며, ^125l-iodotyraminehemisuccinyltaxol은 3일까지는 93.4% 이상으로 안정하였고 또한 7일 경과시에는 86.1% 이상의 순도를 보였다. taxol에 대한 단클론항체(3G5A7)의 역가를 검정하여 1:256의 역가를 나타냄을 확인하였으며, taxol 농도에 따른 표준투여응답곡선은 taxol과 방사표지 taxol 유도체간에 경쟁적으로 사용되어 직선성(R2=0.971)을 나타내었다. 결론: taxol의 경쟁적 방사면역측정법의 방사성 추적자로서 방사성표지 taxol 유도체인 ^125l-iodotyraminehemisuccinyltaxol을 이용한 방법이 유용함을 확인하였다. Purpose: Taxol(Paclitaxel), an antineoplastic agent, has been used in the treatment of ovarian and breast cancers. The determination of optimal Taxol concentrations in human serum was required for enhancing therapeutic effect and maintaining the appropriate Taxol level in blood. This study was aimed to synthesize radiolabeled Taxol derivatives as radiotracer in competitive radioimmunoassay for monitoring Taxol concentrations in blood and to determine the usefulness of its derivatives. Materials and Methods: Hemisuccinyltaxol(HT) was synthesized by esterification of Taxol with succinic anhydride. Tyraminehemisuccinyltaxol(THT) was synthesized by coupling of HT with tyramine using isobutylchloroformate as coupling agent and purified by HPLC. By using chloramine-T(5.25 ㎎/ml, 10㎕) as oxidant agent, THT(4 ㎎/ml, 30㎕) was labeled with ^125I(37 MBq, 1 mCi). To estimate the stability of purified THT, ^125I-iodotyraminehemisuccinyltaxol(^125ITHT) was dissolved in 80% acetonitrile aqueous solution, and the solution was incubated at 4℃ and 37℃ for 7 days. At various time intervals, the stability of THT and ^125ITHT was monitored. The tiler of Taxol monoclonal antibody, 3G5A7, was determined by competitive radioimmunoassay using ^125ITHT as a labeled antigen. A standard dose-response curve was demonstated by Taxol competitive radioimmunoassay. Results: HT and THT were synthesized with 79.9% and 19.5% yield, respectively. The labeling yield of ^125ITHT was 93%. After 7 days, the chemical purity of THT was 96.5% at 4℃, and 97.5% at 37℃. After 3 days, ^125ITHT was stable with 94.7% at 4℃ and 93.4% at 37℃. After 7 days, radiochermical purity was diminished to 88.1% at 4℃ and 86.1% at 37℃. The titer of Taxol monoclonal antibody, 3G5A7, was determined to 1:256. A standard dose-response curve demonstated good colinearity (R^2=0.971) as Taxol concentration-dependent manner. Conclusion: Competitive radioimmunoassay using ^125I-iodotyraminehemsuccinytaxol as radiotracer could be used to monitor for concentration of Taxol in the human serum.